Integrated Biopharma Inc
Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment manufactures vitamins and nutritional supple… Read more
Integrated Biopharma Inc (INBP) - Total Assets
Latest total assets as of September 2025: $25.54 Million USD
Based on the latest financial reports, Integrated Biopharma Inc (INBP) holds total assets worth $25.54 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Integrated Biopharma Inc - Total Assets Trend (2000–2025)
This chart illustrates how Integrated Biopharma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Integrated Biopharma Inc - Asset Composition Analysis
Current Asset Composition (June 2025)
Integrated Biopharma Inc's total assets of $25.54 Million consist of 75.4% current assets and 24.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.5% |
| Accounts Receivable | $5.43 Million | 21.8% |
| Inventory | $9.36 Million | 37.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Integrated Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Integrated Biopharma Inc's current assets represent 75.4% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 14.5% of total assets in 2025, down from 21.3% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is inventory at 37.6% of total assets.
Integrated Biopharma Inc Competitors by Total Assets
Key competitors of Integrated Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
General Mills Inc
NYSE:GIS
|
USA | $32.55 Billion |
|
Maniker F & G Co. Ltd
KQ:195500
|
Korea | ₩123.42 Billion |
|
Xiwang Foodstuffs Co Ltd
SHE:000639
|
China | CN¥6.08 Billion |
|
Nanfang Black Sesame Group Co Ltd
SHE:000716
|
China | CN¥4.57 Billion |
|
CNFC Overseas Fishery Co Ltd
SHE:000798
|
China | CN¥5.88 Billion |
|
Henan Shuanghui Investment & Development Co Ltd
SHE:000895
|
China | CN¥40.64 Billion |
|
Xinjiang Chalkis Co Ltd
SHE:000972
|
China | CN¥1.25 Billion |
|
Daehan Flour Mills Co Ltd
KO:001130
|
Korea | ₩1.61 Trillion |
Integrated Biopharma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Integrated Biopharma Inc generates 2.18x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Integrated Biopharma Inc generates $ 3.24 in net profit.
Integrated Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.12 | 3.04 | 1.34 |
| Quick Ratio | 1.92 | 1.18 | 0.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $14.86 Million | $ 12.28 Million | $ 4.83 Million |
Integrated Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between Integrated Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.45 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | -5.0% |
| Total Assets | $24.90 Million |
| Market Capitalization | $2.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Integrated Biopharma Inc's assets below their book value (0.11 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Integrated Biopharma Inc's assets decreased by 5.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Integrated Biopharma Inc (2000–2025)
The table below shows the annual total assets of Integrated Biopharma Inc from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $24.90 Million | -4.98% |
| 2024-06-30 | $26.21 Million | +3.05% |
| 2023-06-30 | $25.43 Million | +0.72% |
| 2022-06-30 | $25.25 Million | -0.75% |
| 2021-06-30 | $25.44 Million | +10.88% |
| 2020-06-30 | $22.94 Million | +15.94% |
| 2019-06-30 | $19.79 Million | +35.85% |
| 2018-06-30 | $14.57 Million | -4.13% |
| 2017-06-30 | $15.20 Million | +7.89% |
| 2016-06-30 | $14.09 Million | +21.18% |
| 2015-06-30 | $11.62 Million | +0.35% |
| 2014-06-30 | $11.58 Million | -8.15% |
| 2013-06-30 | $12.61 Million | +6.18% |
| 2012-06-30 | $11.88 Million | -12.99% |
| 2011-06-30 | $13.65 Million | -1.43% |
| 2010-06-30 | $13.85 Million | -15.99% |
| 2009-06-30 | $16.48 Million | -47.43% |
| 2008-06-30 | $31.36 Million | -29.07% |
| 2007-06-30 | $44.21 Million | +17.56% |
| 2006-06-30 | $37.60 Million | +43.30% |
| 2005-06-30 | $26.24 Million | -17.51% |
| 2004-06-30 | $31.81 Million | +52.75% |
| 2003-06-30 | $20.83 Million | +108.12% |
| 2002-06-30 | $10.01 Million | +1.72% |
| 2001-06-30 | $9.84 Million | +14.66% |
| 2000-06-30 | $8.58 Million | -- |